nach oben

Erschienen in:

01.11.2014 | Original Research Article

Anti-Oxidative Stress Effect of Loading-Dose Rosuvastatin Prior to Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Prospective Randomized Controlled Clinical Trial

verfasst von: Dong Liang, Qian Zhang, Hexu Yang, Ran Zhang, Wei Yan, Haokao Gao, Jinda Wang, Xiaotian Zhang, Yundai Chen, Feng Cao

Erschienen in: Clinical Drug Investigation | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Administration of a loading dose of a statin (HMG-CoA reductase inhibitor) prior to percutaneous coronary intervention (PCI) contributes to protection from myocardial ischemic–reperfusion injury. This trial was designed to investigate the effect and mechanism of loading-dose rosuvastatin therapy before PCI in patients with acute coronary syndrome.

Methods

One hundred and forty-three patients with acute coronary syndrome were randomized to either the loading-dose (rosuvastatin 40 mg given 4 h before PCI) or conventional-dose (rosuvastatin 10 mg given 4 h before PCI) group. Blood samples were collected before and 0, 24, and 72 h post-PCI for measurement of serum cardiac troponin-I (cTn I), creatine kinase-MB (CK-MB), superoxide dismutase (SOD), reactive oxygen species (ROS), and malondialdehyde (MDA). Echocardiography and the major adverse cardiac/cerebrovascular events (MACCE) rate were followed up for 6 months post-PCI.

Results

Blood serum CK-MB and cTn I were significantly lower in the loading-dose group than in the conventional-dose group at 24 and 72 h post-PCI [CK-MB: 26.90 ± 3.22 vs. 32.96 ± 2.65 IU/L, P = 0.024; 10.79 ± 4.65 vs. 15.18 ± 5.39 IU/L, P = 0.021. cTn I: 0.046 ± 0.007 vs. 0.055 ± 0.002 ng/mL, P = 0.015; 0.027 ± 0.006 vs. 0.041 ± 0.006 ng/mL, P = 0.026]. Echocardiography at 6 months after PCI revealed significant improvement in cardiac function in the loading-dose group compared with the conventional-dose group (P < 0.05). The MACCE rate at 6 months after PCI in the loading-dose group was lower than in the conventional-dose group (P = 0.0428). The levels of MDA and ROS were decreased and the SOD level was significantly higher in the loading-dose group than in the conventional-dose group at 0, 24, and 72 h post-PCI (P < 0.05).

Conclusion

Administration of loading-dose rosuvastatin in patients with acute coronary syndrome prior to PCI exerts myocardial protection by inhibition of oxidative stress.

Nur mit Berechtigung zugänglich

Sardella G, Conti G, Donahue M, Mancone M, Canali E, De Carlo C, et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial. Catheter Cardiovasc Interv. 2013;81(1):E36–43. doi:10.1002/ccd.24403.PubMedCrossRef

Sardella G, Lucisano L, Mancone M, Conti G, Calcagno S, Stio RE, et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013;168(4):3715–20. doi:10.1016/j.ijcard.2013.06.017.PubMedCrossRef

Nusca A, Melfi R, Patti G, Sciascio GD. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future Cardiol. 2010;6(5):579–89. doi:10.2217/fca.10.77.PubMedCrossRef

Zhang M, Que B, Nie SP, Kang J, Ma CS. The effect of pre-hospital statins therapy on incidence of in-hospital death and total MACCE in patients with PCI. J Clin Pharm Ther. 2008;33(6):613–7. doi:10.1111/j.1365-2710.2008.00954.x.PubMedCrossRef

Chen MS, Bhatt DL, American College of Cardiology, American Heart Association. Highlights of the 2002 update to the 2000 American College of Cardiology/American Heart Association acute coronary syndrome guidelines. Cardiol Rev. 2003;11(3):113–21. doi:10.1097/01.CRD.0000064422.16013.ED.PubMedCrossRef

Hajri T, Chanussot F, Ferezou J, Riottot M, Lafont H, Laruelle C, et al. Reduced cholesterol absorption in hamsters by crilvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Eur J Pharmacol. 1997;320(1):65–71.PubMedCrossRef

Lee KW, Felmeden DC, Lip GY. Statins and the assessment of endothelial function. J Intern Med. 2002;251(5):452–3; author reply 3–4.

Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol. 2011;107(12):1710–7. doi:10.1016/j.amjcard.2011.02.336.PubMedCrossRef

Kuo CD. Statins, inflammation, oxidative stress, and atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(4):420–1. doi:10.1111/j.1540-8167.2010.01946.x.PubMedCrossRef

10.

McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(5A):28B–32B.PubMedCrossRef

11.

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012;33(18):2290–6. doi:10.1093/eurheartj/ehs077.PubMedCrossRef

12.

Ishibashi Y, Nakashima S, Matsui T, Yamagishi S. Rosuvastatin restores advanced glycation end product-induced decrease in sirtuin 1 (SIRT1) mRNA levels in THP-1 monocytic cells through its anti-oxidative properties. Int J Cardiol. 2013;169(6):e102–3.PubMedCrossRef

13.

Li XL, Guan RJ, Xu QH, Wu ZY. Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats [in Chinese]. Zhonghua xin xue guan bing za zhi. 2011;39(3):247–53.PubMed

14.

Melfi R, Nusca A, Patti G, Di Sciascio G. Statins and their role in pre-percutaneous coronary intervention. Curr Cardiol Rep. 2010;12(4):295–301. doi:10.1007/s11886-010-0110-0.PubMedCrossRef

15.

Hahn JY, Kim HJ, Choi YJ, Jo SH, Kim HJ, Lee S, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2011;162(6):1026–33. doi:10.1016/j.ahj.2011.08.011.PubMedCrossRef

16.

Westin GG, Armstrong EJ, Bang H, Yeo KK, Anderson D, Dawson DL, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63(7):682–90. doi:10.1016/j.jacc.2013.09.073.PubMedCrossRefPubMedCentral

17.

Yun KH, Shin SN, Ko JS, Rhee SJ, Kim NH, Oh SK, et al. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. J Cardiol. 2012;60(5):383–8. doi:10.1016/j.jjcc.2012.07.008.PubMedCrossRef

18.

Amsterdam EA. Did you know? A predictable “MIRACL”. Prev Cardiol. 2001;4(1):46.PubMedCrossRef

19.

Villines TC. Statin therapy for subclinical atherosclerosis in primary prevention: time to prove it? JACC Cardiovasc Imaging. 2012;5(3):261–3. doi:10.1016/j.jcmg.2011.11.015.PubMedCrossRef

20.

Michalek A. Results of ARMYDA-ACS trial show good outcome of 80 mg atorvastatin pretreatment in patients with acute coronary syndromes undergoing early percutaneous coronary intervention [in Polish]. Kardiologia polska. 2007;65(7):851–2; discussion 3–4.

21.

Fantin Sde S, Wainstein MV, Polanczyk CA, Ledur P, Lazzari CM, Klein C, et al. Inflammatory and oxidative stress markers after intravenous insulin in percutaneous coronary intervention with stent in type 2 diabetes mellitus: a randomized controlled trial. J Clin Endocrinol Metab. 2011;96(2):478–85. doi:10.1210/jc.2010-0256.PubMedCrossRef

22.

Kochiadakis GE, Arfanakis DA, Marketou ME, Skalidis EI, Igoumenidis NE, Nikitovic D, et al. Oxidative stress changes after stent implantation: a randomized comparative study of sirolimus-eluting and bare metal stents. Int J Cardiol. 2010;142(1):33–7. doi:10.1016/j.ijcard.2008.12.105.PubMedCrossRef

23.

Nikolic-Heitzler V, Rabuzin F, Tatzber F, Vrkic N, Bulj N, Borovic S, et al. Persistent oxidative stress after myocardial infarction treated by percutaneous coronary intervention. Tohoku J Exp Med. 2006;210(3):247–55.PubMedCrossRef

24.

Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018–28.PubMedCrossRef

25.

Tian XY, Wong WT, Xu A, Chen ZY, Lu Y, Liu LM, et al. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br J Pharmacol. 2011;164(2b):598–606. doi:10.1111/j.1476-5381.2011.01416.x.PubMedCrossRefPubMedCentral

Titel: Anti-Oxidative Stress Effect of Loading-Dose Rosuvastatin Prior to Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Prospective Randomized Controlled Clinical Trial
verfasst von: Dong Liang
Qian Zhang
Hexu Yang
Ran Zhang
Wei Yan
Haokao Gao
Jinda Wang
Xiaotian Zhang
Yundai Chen
Feng Cao
Publikationsdatum: 01.11.2014
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 11/2014
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-014-0231-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Anti-Oxidative Stress Effect of Loading-Dose Rosuvastatin Prior to Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Prospective Randomized Controlled Clinical Trial

Abstract

Background and Objectives

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

Steady-State Bioavailability of Extended-Release Methylphenidate (MPH-MLR) Capsule vs. Immediate-Release Methylphenidate Tablets in Healthy Adult Volunteers

Initial 3-Weeks’ Apixaban Versus Dual-Antiplatelet Therapy (Clopidogrel and Aspirin) Followed by Clopidogrel Alone in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): Study Protocol for a Randomized Controlled Trial

Levetiracetam Pharmacokinetics in Japanese Subjects with Renal Impairment

Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects